Comment on: "Botulinum Toxin in the Management of Children with Cerebral Palsy"
Paediatr Drugs
.
2019 Dec;21(6):493-495.
doi: 10.1007/s40272-019-00358-2.
Authors
Katherine Langdon
1
,
Lisa Copeland
2
,
Priya Edwards
2
,
Kate Rodwell
2
,
Kim McLennan
2
,
Theresa Carroll
2
,
Sasaka Bandaranayake
2
,
Adam Scheinberg
3
4
,
Mary-Clare Waugh
5
,
Heather Burnett
6
,
Neil Wimalasundera
7
,
Sabine Hennel
8
,
Eewei Lim
9
,
Steve O'Flaherty
10
Affiliations
1
Perth Children's Hospital, Nedlands, WA, Australia.
[email protected]
.
2
Children's Health Queensland Hospital and Health Service, Brisbane, QLD, Australia.
3
Murdoch Children's Research Institute, Parkville, Australia.
4
Department of Paediatrics, University of Melbourne, Melbourne, Australia.
5
The Children's Hospital at Westmead, Westmead, NSW, Australia.
6
HNEkidsRehab, Newcastle, NSW, Australia.
7
Royal Children's Hospital, Parkville, VIC, Australia.
8
Monash Children's Hospital, Clayton, VIC, Australia.
9
Starship Child Health, Auckland, New Zealand.
10
Sydney Children's Hospital Network, Sydney, Australia.
PMID:
31583614
DOI:
10.1007/s40272-019-00358-2
No abstract available
Publication types
Letter
Comment
MeSH terms
Botulinum Toxins, Type A*
Cerebral Palsy*
Child
Humans
Muscle Spasticity
Substances
Botulinum Toxins, Type A